Vertex Pharmaceuticals Incorporated Watch

from 10-Q 10 pages Employment Agreement

from 10-K 1 page Vertex Pharmaceuticals Incorporated Annual Non-Employee Board Compensation Annual Retainer $100,000 Committee Chair Compensation Audit & Finance Committee Chair $30,000 Annual Retainer Management Development & Compensation Committee Chair $25,000 Annual Retainer Corporate Governance & Nominating Committee Chair $25,000 Annual Retainer Science & Technology Committee Chair $25,000 Annual Retainer Committee Membership Fee (Non-Chairs) Audit & Finance Committee Member $15,000 Annual Retainer Management Development & Compensation Committee Member $12,500 Annual Retainer Corporate Governance & Nominating Committee Member $10,000 Annual Retainer Science & Technology Committee Member $10,000 Annual Retainer Lead Independent Director Compensation $55,000 Annual Retainer Annual Equity Grants Annually on May 1, $400,000 in Value-Based Awards, Comprised at the Director's Election of Restricted Stock Units and/or Options •options Are Fully Vested Upon Grant •restricted Stock Units Cliff Vest on the 1 Year Anniversary of the Grant Date Initial Equity Grants on Date Director Joins the Board of Directors, a $400,000 Restricted Stock Unit Award That Vests on the First Anniversary of the Grant Date. Each of Our Non-Employee Directors Is Eligible to Defer the Cash and Restricted Stock Portion of His/Her Compensation Set Forth Above and Elect to Receive Deferred Stock Units That Convert to Common Stock in Specified Circumstances

from 10-K 6 pages Charles F. Wagner [Address] Re: Change of Control Agreement Dear Charles

from 10-K 9 pages Employment Agreement This Employment Agreement (This “Agreement”) Is Made and Entered Into as of This 7th Day of February, 2025, by and Between Vertex Pharmaceuticals Incorporated, a Massachusetts Corporation (Together With Its Successors and Assigns, the “Company”), and Charles F. Wagner, Jr. (The “Executive”). W It N E S S E T H Whereas, the Company and the Executive Desire That the Executive Continue to Serve as an Executive Vice President of the Company as of the Effective Date; And

from 10-K 2 pages Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan Restricted Stock Unit Award

from 10-K 2 pages Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan Restricted Stock Unit Award

from 10-Q 2 pages Amendment No. 3 to Employment Agreement

from 10-Q 8 pages 2024 Amendment to Lease

from 10-Q 8 pages 2024 Amendment to Lease

from 10-K 1 page Vertex Employee Compensation Plan

from 10-K 7 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Vertex Pharmaceuticals Incorporated if Publicly Disclosed. Amendment No. 1 to the Amended and Restated Joint Development and Commercialization Agreement

from 10-K 1 page Vertex Employee Compensation Plan

from 10-K 2 pages Amendment No. 2 to Employment Agreement

from 10-K 1 page Vertex Pharmaceuticals Incorporated Annual Non-Employee Board Compensation Annual Retainer $100,000 Committee Chair Compensation Audit & Finance Committee Chair $30,000 Annual Retainer Management Development & Compensation Committee Chair $25,000 Annual Retainer Corporate Governance & Nominating Committee Chair $25,000 Annual Retainer Science & Technology Committee Chair $25,000 Annual Retainer Committee Membership Fee (Non-Chairs) Audit & Finance Committee Member $15,000 Annual Retainer Management Development & Compensation Committee Member $12,500 Annual Retainer Corporate Governance & Nominating Committee Member $10,000 Annual Retainer Science & Technology Committee Member $10,000 Annual Retainer Lead Independent Director Compensation $40,000 Annual Retainer Annual Equity Grants Annually on May 1, $400,000 in Value-Based Awards, Comprised at the Director's Election of Restricted Stock Units and/or Options •options Are Fully Vested Upon Grant •restricted Stock Units Cliff Vest on the 1 Year Anniversary of the Grant Date Initial Equity Grants on Date Director Joins the Board of Directors, a $400,000 Restricted Stock Unit Award That Vests on the First Anniversary of the Grant Date. Each of Our Non-Employee Directors Is Eligible to Defer the Cash and Restricted Stock Portion of His/Her Compensation Set Forth Above and Elect to Receive Deferred Stock Units That Convert to Common Stock in Specified Circumstances

from 10-K 6 pages Material contract

from 10-K 8 pages Employment Agreement

from 10-K 2 pages Amendment No. 1 to Employment Agreement

from 10-Q 15 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Vertex Pharmaceuticals Incorporated if Publicly Disclosed. Amendment No. 7 Research, Development and Commercialization Agreement, Dated May 24, 2004 by and Between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated

from 10-Q 27 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Vertex Pharmaceuticals Incorporated if Publicly Disclosed. Amendment No. 5 to Research, Development and Commercialization Agreement, Dated May 24, 2004, by and Between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated

from 10-Q 13 pages Amendment No. 1 to Research, Development and Commecialization Agreement (The “Existing Agreement”) Dated May 24, 2004 by and Between Vertex Pharmaceuticals Incorporated (“Vertex”) and Cystic Fibrosis Foundation Therapeutics Incorporated